 |
|
| |
Barrier Therapeutics is a biopharmaceutical company, which was founded to discover, develop and market prescription dermatologic products. We are focused on advancing the science of dermatology in order to provide patients with better therapies. It is this focus that has led to eight products in clinical development, including four in or entering Phase III. Zimycan is the first of these four agents, the first combination product containing miconazole that was designed specifically for Candida associated Diaper Dermatitis. Next in line will be Sebazole, a once daily formulation of ketoconazole for Seborrheic dermatitis and then Hyphanox, a unique 200mg tablet formulation of itraconazole. The fourth product entering Phase III development is Liarozole, the first of a class of molecules known as RAMBAS (Retinoic Acid Metabolism Blocking Agents) for the treatment of Congenital Ichthyosis. By building an innovative and broad pipeline, we are striving to be a global leader in the advancement of dermatologic care. Look to Barrier Therapeutics for innovative solutions to your most challenging dermatologic problems in the near future and for many years to come. For more information on our products and pipeline visit our website at www.barriertherapeutics.com .
Click here to close this window
|
